Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Squibb : Says Study of Opdivo Plus Yervoy Against Carcinoma Did Not Meet Endpoints

07/16/2021 | 07:29am EDT


ę MT Newswires 2021
All news about BRISTOL-MYERS SQUIBB COMPANY
09/20BRISTOL MYERS SQUIBB : FDA Grants Bristol-Myers Squibb Priority Review for Metastatic Mela..
MT
09/20BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Review Brist..
BU
09/20Bristol Myers Squibb Announces FDA Accepts for Priority Review Biologics License Applic..
CI
09/20Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma
DJ
09/17BRISTOL MYERS SQUIBB : Combination Therapy Gets EMA Committee's Backing for Treating Gastr..
MT
09/17BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherap..
BU
09/17Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo with Chemotherapy for Pa..
CI
09/17Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers
DJ
09/16Bristol-Myers Squibb Down Nine Consecutive Days, on Pace for Longest Losing Streak Sinc..
DJ
09/16BRISTOL MYERS SQUIBB : Reports Data From Phase 3 Trial of Opdivo, Yervoy Combination
MT
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 378 M - -
Net income 2021 6 495 M - -
Net Debt 2021 28 289 M - -
P/E ratio 2021 21,0x
Yield 2021 3,24%
Capitalization 135 B 135 B -
EV / Sales 2021 3,51x
EV / Sales 2022 3,16x
Nbr of Employees 30 250
Free-Float 76,0%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 60,63 $
Average target price 75,39 $
Spread / Average Target 24,4%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY-2.26%134 727
JOHNSON & JOHNSON4.75%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.40%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY37.51%206 972